Report of chronic myeloid leukemia from All India Institute of Medical Sciences, 1990-2010

Mishra, Pravas; Seth, Tulika; Sazawal, Sudha; Mahapatra, Manoranjan; Saxena, Renu

doi:10.4103/0971-5851.123712

Cited by 16 publications

(25 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study comprised 269 CML patients with imatinib treatment failure. The median age was 36 years (18-66 years) and the sex ratio was 1.7:1, whereas in other studies by Quintas Cardama Alfonso et al .,[ 17 ] Jabbour et al .,[ 18 ] Cortes et al .,[ 19 ] Rajappa et al .,[ 20 ] and Mishra et al .,[ 21 ] the median age was 52 years (18–79), 57 years (25–82), 51 years (17–96), 36 years (18–65), and 35 years, respectively. The sex ratio was 1.08:1, 1.6:1, 2.7:1, and 1.6:1 in the studies done by Quintas Cardama Alfonso et al .,[ 17 ] Jabbour et al .,[ 18 ] Rajappa et al .,[ 20 ] and Mishra et al .,[ 21 ] respectively.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: Single-institutional experience over 13 years

Chaitanya

Kumar

Bala

et al. 2017

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

Introduction:BCR-ABL1 kinase domain mutations represent the most frequent mechanism of resistance to tyrosine kinase inhibitor (TKI) therapy, being detected in 40%–50% of imatinib-resistant patients with chronic myeloid leukemia in chronic phase (CML-CP). Over 100 BCR-ABL1 single-point mutations have been reported in patients with imatinib-resistant CML. There were few studies reported from India on BCR-ABL kinase mutations in imatinib failure patients. We present our data on imatinib resistance mutation analysis (IRMA) and use of imatinib dose hike and 2nd-generation TKI at our institute.Materials and Methods:All patients with a diagnosis of CML in a university hospital from June 2003 to July 2016 and who were tested for IRMA in view of imatinib failure, those in CP, and age <18 years were included in the study.Results:A total of 2110 cases of CML reviewed and 269 cases of CML with imatinib failure were analyzed. The male to female ratio was 1.7:1. The median age at presentation was 36 years (range: 18–66 years). Among these, 26% were primary failures and 74% were secondary failures. The treatment was modified either as imatinib dose hike or nilotinib/dasatinib. Molecular response at 12 months was achieved in 25.7% in imatinib dose hike, 46.6% in nilotinib, and 53.8% in dasatinib arms. The 4-year overall survival in mutation detected group was 37.5% and in nonmutated group was 87.7%.Conclusion:Imatinib-resistant mutations were more common in the cases with secondary failure though not statistically significant. T315I mutation was the common mutation found in the study. Imatinib dose hike to the failure cases resulted in optimal hematological response rates.

show abstract

Section: Discussionmentioning

confidence: 99%

“…We stratified patients into different risk groups using three scoring systems; nevertheless, Sokal score was used in most of the studies[ 18 21 22 23 ] and in comparison to Western studies, this study had more number of intermediate and high-risk Sokal score.…”

Section: Discussionmentioning

confidence: 99%

The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: Single-institutional experience over 13 years

Chaitanya

Kumar

Bala

et al. 2017

Indian J Med Paediatr Oncol

View full text Add to dashboard Cite

show abstract

“…In most of the Indian study median age of presentation range in between 30 to 40 year (Parikh, 2002;Mishra et al, 1990;Prasad and Singh, 2002;Jabbour et al, 2006;Bansal et al, 2013) . Men are affected more than female in both western and Indian study.…”

Section: 1% By Qpcr) Cmr-complete Molecular Response (No Detectablmentioning

confidence: 99%

“…Grade 3 4 hematological toxicity was seen in 11% of patients (anemia 2%, thrombocytopenia 5.5% and neutropenia 11%). In Mishra et al (1990) Anaemia in 12.5%, Neutropenia in 25% and Thrombocytopenia in 37.5% was seen as hematological toxicity of Imatinib.5 The main side effects noted with Imatinib include fatigue, edema, nausea, diarrhea, muscle cramps, and rash. Cutaneous reactions with Imatinib therapy occur in approximately 15 percent of patients, Hepatotoxicity is uncommon, occurring in approximately 3 percent of patients, usually within 6 months of the onset of Imatinib use (Hensley and Ford, 2003;Sanchez-Gonzalez, 2003;Cross et al, 2006;Singhal et al, 2016).…”

Section: 1% By Qpcr) Cmr-complete Molecular Response (No Detectablmentioning

confidence: 99%

Treatment of chronic myeloid leukemia with Generic Imatinib in patients from Northeastern part of India

Samrat

Meena

Chakravarty

et al. 2019

ijrps

View full text Add to dashboard Cite

Imatinib is now used as the irst-line drug to treat CML patient. However, the emergence of resistance to Imatinib in CML patient, the side effect of bone marrow suppression, luid overload and gastritis are a major limitation of the use of Imatinib in the treatment of CML. This study was conducted to see the therapeutic response and side effect pro ile of generic Imatinib Mesylate in newly diagnosed CML patients. All cases of CML were given generic Imatinib and followed prospectively with a minimum follow-up of 6 months. They were followed at an interval of 2 weeks till complete hematologic response, thereafter at an interval of 6 to 8 weeks. Cytogenetic and molecular response at the end of one year also evaluated. Among 36 CML patients, 33 were in chronic phase 2 in accelerated phase and 1 in blast crisis while 35 were Philadel-phia+ve and 1 was ph-ve at initial presentation. Minimum duration to achieve CHR was 2 weeks with a mean of 5 weeks. At 3 month except one 35 patients achieved CHR (97%). Out of 36 patients, 27 were subjected for Philadelphia chromosome at one year which shown 23 patients (85.18%) achieved a major cytogenetic response. 8 (38%) patients achieved a major molecular response and one patient (4.76%) was having a complete molecular response at one year. 8 (22.22%) patients developed hematological toxicity to Imatinib with Pancytopenia most common. In conclusion, Generic Imatinib is having an excellent therapeutic response in CML patients although higher response rate may be due to smaller sample size and lesser duration of follow up.

show abstract

“…Below the age of one year, CML is extremely rare. In India, CML is usually seen in children older than 12 years6. The National Cancer Registry Programme of India registers all childhood leukaemia cases in a single group; hence, there is no separate data collection for paediatric CML7.…”

Section: Introductionmentioning

confidence: 99%

Paediatric chronic myeloid leukaemia

Pushpam

Bakhshi

2019

Indian Journal of Medical Research

View full text Add to dashboard Cite

Paediatric chronic myeloid leukaemia (CML) has biological and clinical differences from adult CML. Management of paediatric CML presents unique challenges in growing children, and there are no specific guidelines for paediatric CML. This review focusses on the clinical characteristics, diagnostic issues and management of paediatric CML. Major studies that provide the basis of managing paediatric CML are summerized here. Studies conducted on adult CML patients were used to guide the management of places where studies were lacking in paediatric CML. Recently, dasatinib and nilotinib have been approved for treatment of paediatric CML, and their role has been discussed in the current management perspective. Allogeneic transplant, fertility and vaccination in paediatric CML, have also been discussed.

show abstract

Report of chronic myeloid leukemia from All India Institute of Medical Sciences, 1990-2010

Cited by 16 publications

References 9 publications

The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: Single-institutional experience over 13 years

The role of mutation testing in patients with chronic myeloid leukemia in chronic phase after imatinib failure and their outcomes after treatment modification: Single-institutional experience over 13 years

Treatment of chronic myeloid leukemia with Generic Imatinib in patients from Northeastern part of India

Paediatric chronic myeloid leukaemia

Contact Info

Product

Resources

About